Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Altor Bioscience Corporation Identifier:
First received: December 9, 2009
Last updated: January 12, 2015
Last verified: January 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2013
  Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: July 23, 2013